What Is BPC-157? Origin, Structure & Evidence Status

Short definition

BPC-157 is a synthetic fifteen-amino-acid peptide. The literature describes it as a pentadecapeptide and often names it Body Protection Compound-157. That is a chemical and historical identity, not a clinical verdict.^1,5

This page answers “what is it?” It does not summarize mechanisms, does not weigh tendon or gut evidence, and does not interpret FDA status. Those questions have their own pages in the BPC-157 research hub.

The definition matters because many pages mix three different things: the name of a peptide, the volume of animal papers, and a promised result in people. Here only the first stays. The other two belong on evidence pages, not on an identity card.

Body Protection Compound terminology

The acronym BPC comes from Body Protection Compound. A 1993 paper presents BPC as a gastric-juice peptide and describes a fifteen-amino-acid fragment, BPC 157, as the portion then thought essential for the activity under study.¹

That name origin does not show that the peptide “protects the body” in people. It is laboratory nomenclature. In online marketing, Body Protection Compound is often used as if it were already a therapeutic classification. Here it is treated only as the history of the name.

Peptide length and sequence

Fifteen amino acids is the length that defines a pentadecapeptide. The one-letter sequence commonly cited is GEPPPGKPADDAGLV, equivalent to Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.^4,5

A sequence identifies a polypeptide. It does not indicate a medical indication, does not set an amount to use, and does not equal an approved drug. It also does not turn an analyzed lot into a therapeutic product.

When a certificate of analysis or a research catalog repeats that sequence, it is speaking about analytical identity. That match does not carry over the endpoints of a rat model or the result of a two-person pilot.

Origin and nomenclature history

Early papers place the interest in a gastric and experimental “organoprotection” context. The 1993 article is useful for understanding where the name and the fifteen-amino-acid cut came from. It is not a clinical trial and should not be read as evidence of human use.¹

Later rat work, for example on gastric mucosa and the nitric-oxide system, continued that experimental line. It remains preclinical.²

A 2026 review summarizes more than three decades of that development and states that pharmaceutical development remains rudimentary.⁵

What researchers have studied

Researchers have used BPC-157 in animal models and cell systems. Recurring areas include experimental gastric injury, tendon and musculoskeletal soft tissue, and vascular signaling. Those are laboratory lines of work.^2,3,7

A 2025 orthopedic review, searching through June 2024, illustrates the proportion: 35 preclinical studies and one clinical study. That count is not a meta-analysis of human efficacy; it is a map of where the literature sits.⁷

This cluster does not try to catalog the hundreds of animal papers that exist. It chooses representative sources and reviews that state their limits. Inflating the bibliography does not change the class of evidence.

Preclinical versus human evidence

In this cluster, preclinical means work in animals, explants, or cells. That work can be technically serious and still fail to answer the clinical question. The published human evidence we use as an anchor is a 2025 pilot with two participants.^6,5

Two people are not enough to speak of general safety. The detail, and what such a small sample cannot show, is in BPC-157 in humans.

Current approval status

BPC-157 is not an FDA-approved drug. There is no approved pharmaceutical formulation and no validated human dosing regimen. In July 2026 an advisory compounding committee discussed BPC-157-related bulk substances; that discussion is not approval.^5,8

In sport, WADA’s 2026 Prohibited List names BPC-157 in class S0, non-approved substances. That is anti-doping status, not a medical ruling.⁹

What BPC-157 is not proven to do in humans

• It is not proven to treat tendon or ligament injury in people.
• It is not proven to cure or control human gastrointestinal disease, including ulcerative colitis.
• It is not proven to regenerate human muscle, nerve, or other tissue in a clinical sense.
• It is not a “healing peptide” as a scientific category. That phrase is marketing language, not an established classification.

Research documentation versus clinical evidence

A certificate of analysis can confirm lot identity and purity. That is analytical documentation. It is not evidence that the peptide does something in a human body. The BPC-157 certificate archive and this definition answer different questions.

Next reading

If the question is how the peptide has been proposed to act in the laboratory, continue to proposed mechanisms. If the question is what exists in humans, go to human studies. The cluster map is the BPC-157 hub.